{"id":"kmt2a","name":"KMT2A (MLL) rearrangement","symbol":"KMT2A","route":"/targets/kmt2a/","asOf":"2026-09-07","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7132","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118058","uniprot":"https://www.uniprot.org/uniprotkb/Q03164/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q03164","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1293299","open-targets":"https://platform.opentargets.org/target/ENSG00000118058","civic":"https://civicdb.org/genes/4297/summary","oncokb":"https://www.oncokb.org/gene/KMT2A","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KMT2A","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=KMT2A","depmap":"https://depmap.org/portal/gene/KMT2A?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000118058-KMT2A","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4297","omim":"https://www.omim.org/entry/159555"}],"products":[{"id":"etoposide","name":"Etoposide","status":"approved","modality":"Topoisomerase II inhibitor (podophyllotoxin derivative)","route":"/drugs/etoposide/"},{"id":"ziftomenib","name":"Ziftomenib","status":"approved","modality":"Small-molecule menin inhibitor","route":"/drugs/ziftomenib/"}],"trials":[{"id":"ielsg43","name":"MATRix/IELSG43","nct":"NCT02531841","phase":"3","status":"positive"},{"id":"nct03182244","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","nct":"NCT03182244","phase":"3","status":"completed"},{"id":"nct05224141","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","nct":"NCT05224141","phase":"3","status":"active"},{"id":"nct02521493","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","nct":"NCT02521493","phase":"3","status":"active"},{"id":"nct04665856","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","nct":"NCT04665856","phase":"3","status":"completed"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"ahod1331","name":"AHOD1331","nct":"NCT02166463","phase":"3","status":"positive"},{"id":"capstone-1","name":"CAPSTONE-1","nct":"NCT03711305","phase":"3","status":"positive"},{"id":"acns0333","name":"ACNS0333","nct":"NCT00653068","phase":"3","status":"positive"},{"id":"actg-a5263","name":"ACTG A5263/AMC 066","nct":"NCT01435018","phase":"3","status":"positive"},{"id":"inter-b-nhl-ritux-2010","name":"Inter-B-NHL Ritux 2010","nct":"NCT01516580","phase":"3","status":"positive"},{"id":"ahl2011","name":"AHL2011","nct":"NCT01358747","phase":"3","status":"positive"},{"id":"calgb-50303","name":"Alliance/CALGB 50303","nct":"NCT00118209","phase":"3","status":"negative"},{"id":"anbl0531","name":"ANBL0531","nct":"NCT00499616","phase":"3","status":"positive"},{"id":"interfant-06","name":"Interfant-06","nct":"NCT00550992","phase":"3","status":"mixed"},{"id":"aren0533","name":"COG AREN0533","nct":"NCT00379340","phase":"3","status":"positive"},{"id":"nct00557193","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","nct":"NCT00557193","phase":"3","status":"completed"},{"id":"eortc-h10","name":"EORTC/LYSA/FIL H10","nct":"NCT00433433","phase":"3","status":"mixed"},{"id":"hd18","name":"GHSG HD18","nct":"NCT00515554","phase":"3","status":"positive"},{"id":"euramos-1","name":"EURAMOS-1","nct":"NCT00134030","phase":"3","status":"negative"},{"id":"nct00004054","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","nct":"NCT00004054","phase":"3","status":"completed"},{"id":"getug-13","name":"GETUG 13","nct":"NCT00104676","phase":"3","status":"positive"},{"id":"nct00109031","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","nct":"NCT00109031","phase":"3","status":"completed"},{"id":"aews0031","name":"AEWS0031","nct":"NCT00006734","phase":"3","status":"positive"},{"id":"jcog9801","name":"JCOG9801","nct":"NCT00145002","phase":"3","status":"mixed"},{"id":"ialt","name":"IALT (International Adjuvant Lung Cancer Trial)","phase":"3","status":"positive"},{"id":"turrisi-intergroup-0096","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","phase":"3","status":"positive"},{"id":"nct05566041","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","nct":"NCT05566041","phase":"3","status":"active"},{"id":"nct06564844","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","nct":"NCT06564844","phase":"3","status":"active"},{"id":"nct07728955","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","nct":"NCT07728955","phase":"3","status":"planned"},{"id":"nct07502300","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","nct":"NCT07502300","phase":"3","status":"recruiting"},{"id":"nct07802821","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","nct":"NCT07802821","phase":"3","status":"planned"},{"id":"nct07005128","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","nct":"NCT07005128","phase":"3","status":"active"},{"id":"nct04293562","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","nct":"NCT04293562","phase":"3","status":"recruiting"},{"id":"nct06230224","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","nct":"NCT06230224","phase":"3","status":"active"},{"id":"adiuvo-2","name":"ADIUVO-2","nct":"NCT03583710","phase":"3","status":"recruiting"},{"id":"agct1531","name":"AGCT1531","nct":"NCT03067181","phase":"3","status":"recruiting"},{"id":"nct07625644","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","nct":"NCT07625644","phase":"3","status":"recruiting"},{"id":"nct00703820","name":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","nct":"NCT00703820","phase":"3","status":"completed"},{"id":"nct00003436","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","nct":"NCT00003436","phase":"3","status":"completed"},{"id":"nct00002719","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","nct":"NCT00002719","phase":"3","status":"completed"},{"id":"nct00002658","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","nct":"NCT00002658","phase":"3"},{"id":"nct01993810","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","nct":"NCT01993810","phase":"3","status":"active"},{"id":"nct07472517","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","nct":"NCT07472517","phase":"3","status":"recruiting"},{"id":"nct07544654","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","nct":"NCT07544654","phase":"3","status":"recruiting"},{"id":"euronet-phl-c2","name":"EuroNet-PHL-C2","nct":"NCT02684708","phase":"3","status":"completed"},{"id":"nct04221035","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","nct":"NCT04221035","phase":"3","status":"recruiting"},{"id":"nct01117441","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","nct":"NCT01117441","phase":"3","status":"completed"},{"id":"nct07008716","name":"Omitting CTV for Primary Tumor in LS-SCLC","nct":"NCT07008716","phase":"3","status":"recruiting"},{"id":"nct06712355","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","nct":"NCT06712355","phase":"3","status":"recruiting"},{"id":"nct07007312","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","nct":"NCT07007312","phase":"3","status":"recruiting"},{"id":"nct04380636","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","nct":"NCT04380636","phase":"3","status":"active"},{"id":"nct03811002","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","nct":"NCT03811002","phase":"3","status":"active"},{"id":"nct04092283","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","nct":"NCT04092283","phase":"3","status":"active"},{"id":"nct05624996","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","nct":"NCT05624996","phase":"3","status":"recruiting"},{"id":"tiger-trial","name":"TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours","nct":"NCT02375204","phase":"3","status":"active"},{"id":"nct00136084","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","nct":"NCT00136084","phase":"3","status":"completed"},{"id":"nct03206671","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","nct":"NCT03206671","phase":"3","status":"active"},{"id":"nct01064466","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","nct":"NCT01064466","phase":"2/3","status":"active"},{"id":"myelomatch","name":"myeloMATCH","nct":"NCT05564390","phase":"platform","status":"recruiting"},{"id":"nct04745689","name":"Study of AZD2811 + Durvalumab in ES-SCLC","nct":"NCT04745689","phase":"2","status":"active"},{"id":"anbl17p1","name":"ANBL17P1","nct":"NCT03786783","phase":"2","status":"positive"},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","nct":"NCT01700946","phase":"2","status":"completed"},{"id":"acns0121","name":"ACNS0121","nct":"NCT00027846","phase":"2","status":"positive"},{"id":"acns1123","name":"ACNS1123","nct":"NCT01602666","phase":"2","status":"completed"},{"id":"bmt-ctn-0803","name":"BMT CTN 0803","nct":"NCT01141712","phase":"2","status":"positive"},{"id":"acns0122","name":"ACNS0122","nct":"NCT00047320","phase":"2","status":"completed"},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","nct":"NCT00057811","phase":"2","status":"completed"},{"id":"smile-enktl","name":"SMILE","phase":"2","status":"positive"},{"id":"nct07623616","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","nct":"NCT07623616","phase":"2","status":"recruiting"},{"id":"nct06177925","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","nct":"NCT06177925","phase":"2","status":"recruiting"},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","nct":"NCT07538271","phase":"2","status":"planned"},{"id":"nct07245446","name":"A Study of Ivonescimab in First-Line ES-SCLC","nct":"NCT07245446","phase":"2","status":"recruiting"},{"id":"nct05844150","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","nct":"NCT05844150","phase":"2","status":"active"},{"id":"nct07155174","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","nct":"NCT07155174","phase":"2","status":"recruiting"},{"id":"nct07268040","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","nct":"NCT07268040","phase":"2","status":"recruiting"},{"id":"nct06663098","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","nct":"NCT06663098","phase":"2","status":"recruiting"},{"id":"nct05903092","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","nct":"NCT05903092","phase":"2","status":"recruiting"},{"id":"nct06449209","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","nct":"NCT06449209","phase":"2","status":"active"},{"id":"nct07296809","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","nct":"NCT07296809","phase":"2","status":"recruiting"},{"id":"nct03458260","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","nct":"NCT03458260","phase":"2","status":"completed"},{"id":"nct07583511","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","nct":"NCT07583511","phase":"2","status":"recruiting"},{"id":"nct06813079","name":"Using Tumor Models to Determine Treatments","nct":"NCT06813079","phase":"2","status":"recruiting"},{"id":"komet-001","name":"KOMET-001","nct":"NCT04067336","phase":"1/2","status":"positive"},{"id":"augment-101","name":"AUGMENT-101","nct":"NCT04065399","phase":"1/2","status":"positive"},{"id":"nct07227597","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","nct":"NCT07227597","phase":"1/2","status":"recruiting"},{"id":"nct06741644","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","nct":"NCT06741644","phase":"1/2","status":"recruiting"},{"id":"nct05652686","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","nct":"NCT05652686","phase":"1/2","status":"recruiting"},{"id":"nct05533775","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","nct":"NCT05533775","phase":"1/2","status":"recruiting"},{"id":"nct07730515","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","nct":"NCT07730515","phase":"1/2","status":"recruiting"},{"id":"nct06030258","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","nct":"NCT06030258","phase":"1/2","status":"recruiting"},{"id":"nct06110572","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","nct":"NCT06110572","phase":"1/2","status":"recruiting"},{"id":"nct03793478","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","nct":"NCT03793478","phase":"1/2","status":"active"},{"id":"nct07472647","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","nct":"NCT07472647","phase":"1/2","status":"planned"},{"id":"zen-3694-platinum-nut","name":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)","nct":"NCT05019716","phase":"1/2","status":"recruiting"},{"id":"lace-pooled-analysis","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","phase":"observational","status":"positive"}],"pathways":[],"companies":["bms","kura-oncology"],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}